Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

Martin Metz +2 more

On demand materials

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Dermatology

45 min

expert video

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

Dermatology

10 min

expert video

Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation

Dermatology

10 min

expert video

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation

Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

Dermatology

10 min

expert video

Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

Learning objectives

Recognize the heterogeneity of CSU, including clinical presentation, comorbidities, and therapeutic challenges
Describe the multifaceted pathophysiology of CSU, including key inflammatory mechanisms
Integrate clinical heterogeneity, therapeutic response, and key immune pathways to optimize CSU patient care

About these experts

Allergy/Immunology

Martin Metz

Professor in the Department of Dermatology and Allergy, Head of Translational Research, and Deputy Head of Clinical Trials | Charité – Universitätsmedizin, Berlin, Germany

Dermatology

MD, MSc, FRCPC

Elena Netchiporouk

Assistant Professor, Division of Dermatology, McGill University

Dermatology

MD, MS

Jason Hawkes

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IcelandChange country/region